Introduction
Left ventricular non-compaction cardiomyopathy (LVNC) is an increasingly recognized cause of heart failure, arrhythmia, thromboembolism, and sudden cardiac death. We sought here to dissect its genetic causes, phenotypic presentation and outcome.
Methods and results
In our registry with follow-up of in the median 61 months, we analysed 95 LVNC patients (68 unrelated index patients and 27 affected relatives; definite familial LVNC = 23.5%) by cardiac phenotyping, molecular biomarkers and exome sequencing. Cardiovascular events were significantly more frequent in LVNC patients compared with an age-matched group of patients with non-ischaemic dilated cardiomyopathy (hazard ratio = 2.481, P = 0.002). Stringent genetic classification according to ACMG guidelines revealed that TTN, LMNA, and MYBPC3 are the most prevalent disease genes (13 patients are carrying a pathogenic truncating TTN variant, odds ratio = 40.7 , Confidence interval = 21.6-76.6, P < 0.0001, percent spliced in 76-100%). We also identified novel candidate genes for LVNC. For RBM20, we were able to perform detailed familial, molecular and functional studies. We show that the novel
Introduction
Left ventricular non-compaction cardiomyopathy (LVNC, noncompaction cardiomyopathy = NCCM) is characterized by the presence of excessive left ventricular trabeculae, deep intratrabecular recesses, and a thin compacted myocardial layer. 1 The phenotype of left ventricular non-compaction or hypertrabeculation is an increasingly recognized finding. 2 It also became clear that the detection of this morphological trait is not sufficient to define a pathological condition, as recently found in a population-based imaging study. 1, 3 Hence, estimating the prevalence of cases with a non-compaction phenotype and that of cases that are also prone to develop the typical triad consisting of heart failure, arrhythmia, and embolism is difficult, presenting a unique challenge for larger, prospective trials to assess its pathogenesis, genetic aetiology, management, and outcomes. 4 The pathogenesis of LVNC is not fully resolved. The inherited phenotype can arise due to a gene mutation that disrupts the physiological compaction of the developing embryonic myocardium, a process that normally progresses from the base to the apex of the heart. Other cases are observed sporadically or may even be acquired as observed in highly-trained athletes or in pregnant women. 2, 5 Also, in families with other types of cardiomyopathy (HCM, DCM), a noncompaction phenotype may be found, which raises the question if LVNC is a distinct cardiomyopathy or a sub-trait. While the American Heart Association (AHA) classifies LVNC as an independent genetic cardiomyopathy, the European Society of Cardiology (ESC) defined it as an unclassified entity 6 . From differently sized cohorts of paediatric or adult cases, it can be estimated that 18-44% of LVNC cases are genetic, 7, 8 with autosomal dominant transmission being the by far most common mode of inheritance, followed by X-linked and maternal modes. 9 The available, mostly small-sized cohort studies showed that various unrelated genes are potential disease causes. The genes that have been reported mainly encode for sarcomeric, Z-disc and nuclear-envelope proteins including ACTC1, MYH7, MYBPC3, TNNT2, TPM1, TTN, LDB3, LMNA, and DTNA. [10] [11] [12] [13] [14] Others encode mitochondrial proteins such as TAZ, 12 regulators of the NOTCH pathway, 15 or even ion channels such as HCN4 as reported recently by our groups. 16 In the present analysis of the 'Genetics in Non-Compaction Registry', we aimed to clinically characterize a larger cohort of symptomatic LVNC cases, assess their longitudinal follow-up in comparison to DCM and investigate the prevalence of known and novel LVNC disease genes. For the first time, we link genetic variants in RBM20 with LVNC and precisely delineate the molecular downstream effects by RNA sequencing, titin protein analysis, and functional assays. We provide the first comprehensive landscape of genetic variation in LVNC by applying stringent ACMG criteria for classification and nomenclature, supporting genetic testing and counselling of patients.
Materials and methods

Patient recruitment and clinical evaluation
Consecutive symptomatic index patients with LVNC presenting at participating tertiary centres were enrolled if they had given written informed consent for clinical investigations and genetic testing. The echocardiographic diagnosis for LVNC was based on the criteria of Stöllberger et al. 17 and Jenni et al. 18 A subgroup of index patients additionally received MRI and fulfilled the criteria by Petersen et al. 19 For more details, please see Supplementary data online, methods.
Biomaterial processing, genotyping, and genetic mapping
A peripheral blood sample was collected from each participant. Sequencing was performed in-house on an Illumina HiSeq 2000. Demultiplexing of the raw sequencing reads and generation of the fastq files was done using CASAVA v. 1.82 . 20 Variant calling and quality filtering of variants were performed with Genome-Analysis-Toolkit. 21 For annotation of genes and functional variant effects, we primarily used ANNOVAR. [22] [23] [24] For known LVNC disease genes (Figure 2 ), we applied ACMG criteria. 25 
Results
Ventricular arrhythmias are frequent manifestations of left ventricular non-compaction cardiomyopathy
In total, n = 95 probands with LVNC (68 index patients and 27 affected relatives) were investigated on a phenotypic and genetic level (51 from Univ. Heidelberg, 34 from Univ. Wuhan, and 10 from Univ. Berlin).
The baseline clinical characteristics of the index patients at time of blood sampling are listed in Supplementary material online, Table S1 . In all, 23 .5% of the patients had a definite familial disease defined by at least one additionally affected first-degree relative in the family, who was available for clinical studies at one of the centres (16 pedigrees) and showed the full phenotype of LVNC. Follow-up was in the median 61 months. During follow-up of index cases, seven patients (10.3%) received heart transplantation due to progressive disease. Clinically relevant arrhythmias such as atrial fibrillation (AF) (29.4%) and ventricular tachycardia (VT/VF) (35.3%) were frequently documented findings. As much as 18.2% of implantable cardioverter defibrillator (ICD) carriers had an appropriate ICD shock. All outcomerelated events during follow-up are listed in Table 1 .
Distribution of non-compacted myocardial segments was as previously shown typical for LVNC, with apical/lateral segments being mainly affected, which was not observed in a cohort with (nonischaemic) DCM patients ( Figure 1A) . Left-ventricular ejection fraction was in the mean moderately decreased (LVEF 38% ± 15.3), attributed to the fact that only symptomatic cases of LVNC were studied ( Figure 1B) , while accidental findings of LVNC or probands from population-based studies were not included. The number of composite events including cardiovascular (CV) death, sudden cardiac death (SCD), aborted SCD [appropriate ICD shock, reported sustained ventricular tachycardia, or cardiopulmonary resuscitation (CPR)], or HTx was significantly higher in LVNC index cases compared with a cohort of age-matched DCM patients (HR = 2.481, P = 0.002) ( Figure 1C) . CV death was 10.8% in LVNC (7 from 65) vs. 4 .9% in DCM patients (12 from 247); VT was 30.8% in LVNC (20 from 65) vs. 5 .7% in DCM patients (14 from 247); HTx rate was 10.8 in LVNC (7 from 65) vs. 2.4% in DCM patients (6 from 247) and CPR rate was 4.6% in LVNC (3 from 65) vs. 3.6 in DCM patients (9 from 247). The LVEF was higher in the LVNC group compared with the DCM cohort, showing that the arrhythmogenic substrate in LVNC is most likely not solely based on reduced ejection fraction.
Prevalence of pathogenic variants in known left ventricular non-compaction cardiomyopathy-associated gene loci To genetically characterize the enrolled patients with LVNC, we performed next-generation exome sequencing in altogether 106 subjects (68 unrelated LVNC probands, 27 affected, and 11 healthy relatives). When only considering the established disease genes for LVNC, we find in 38.2% of index patients a rare variant that is classified as 'pathogenic' according to the stringent 'American College of Medical Genetics and Genomics' (ACMG) guidelines for the interpretation of sequence variants ( Figure 2 , see Supplementary material online, Table S4 ).
The most frequently affected gene was the sarcomeric elastic-fibre gene TTN, which was very recently described to be associated with LVNC.
14 From 13 patients that had a pathogenic TTN variant, 13
were truncating variants due to a frameshift insertion/deletion or Stop-gain, which is a new finding for LVNC and 1 patient had additionally a mis-sense variant. The percent spliced in (PSI) values for the variant-harbouring exons was 100% in 11 cases of truncating variants, for 1 it was 76% and 1 was within exon 48 were no reliable PSI annotation is given [https://cardiodb.org (August 2017)]. The missense variant p.G4714D was also in an exon with PSI of 100%. The ODDs ratio for enrichment of truncating TTN variants compared with EXaC was 40.7 (95% confidence interval: 21.6-76.6; P < 0.0001) and for none of the pathogenic variant the associated confidence interval included the 1 (P < 0.0001) (see Supplementary material on line, Table S4 ).
The truncating TTN variants were mainly located in the A-band ( Figure 3A) , which is a region that harbours most pathogenic titin variations. From three Stop-gain variant-carriers, we were able to perform mRNA-sequencing from myocardial biopsies, showing that nonsensemediated RNA-decay (NMD) is the likely pathomechanism leading to loss-of-function of the titin-allele (bar graphs on top of Stop-gain variants). 31 In four pedigrees, we found segregation of one mis-sense and three frameshift TTN variants with the LVNC phenotype ( Figure 3B ). The second most commonly affected disease gene was LMNA (5%). For MYBPC3, which is carrying a pathogenic variant in 4% of the index patients, we report co-segregation of a Splice-variant in a large family with nine affected individuals all having cardiac non-compaction cardiomyopathy (see Supplementary material online, Figure S2 ). For validation, we performed Sanger sequencing and confirmed this variant as well as randomly picked further variants, which have been classified as pathogenic in TTN, LMNA, MYBPC3, or MYH7 (see Supplementary ma terial online, Table S2 and Figures S3 and S4) . Using this very stringent classification, more than 38.2% can be explained by a pathogenic variant in a known LVNC disease locus. However, this underlines that in several probands with either sporadic or familial disease, a currently unknown gene could be causally involved. As such, we find in candidate genes derived from LVNC animal models, potentially causal variants in the TTN-interaction partner Obscurin (OBSCN), 32 which is an established disease gene for DCM and HCM in humans 33, 34 (see Supplementary material online, Figure   S5A ). In our cohort, Obscurin variants were located near the Immunoglobin I-set or protein kinase region of the protein.
Other candidate genes include NCOR2 and XIRP2, both resulting in LVNC in mice models when depleted (see Supplementary material online, Figure S5B and C). In carriers of variants in these three candidate genes, no family members were available to show segregation. Hence, the pathogenic role remains speculative.
RBM20 as a novel disease gene for left ventricular non-compaction cardiomyopathy
Using our whole-exome sequencing strategy, we stratified identified sequence variants for potential pathogenicity using in-silico prediction and further genetic and clinical work-up. Figure 4A , see Supplementary material online, Table S5 ), the index patient (III.2) was diagnosed with LVNC at age of 17. He underwent cardiac transplantation due to progressive disease at the age of 21. The patient's mother (II.3) also presented with severely reduced LVEF (20%) and with left ventricular non-compaction/ hypertrabeculation at age 39 ( Figure 4B) . Non-sustained ventricular tachycardia (nsVT) was recorded in her Holter-ECG. Accordingly, she received an ICD for primary prevention. Endomyocardial biopsies of the index patient and his mother showed severe myocardial fibrosis without signs of myocarditis ( Figure 4B) . The index patient's brother (III.1) died at the age of 16 as a consequence of tetralogy of Fallot (TOF). His grandmother (I.2) suffered SCD at age 59. His uncle (II.2) was also known to have non-ischaemic heart failure. No cardiac image sequences were available to exclude non-compaction or hypertrabeculation.
The exonic rare variant (RBM20: p.R634L, c.G1901T) identified by NGS was found in both available patients and was validated by Sanger sequencing ( Figure 4C ). This novel variant is located in exon 9 and the amino acid change affects the arginine/serine-rich (RS) domain of RBM20, which is highly conserved across species ( Figure 4C) . 'PROVEAN', 'SIFT', and 'Poly-Phen2' predicted the functional effect of the R634L variant to be 'deleterious' (PROVEAN score = -2.67 and SIFT score = 0) and 'probably damaging' (Poly-Phen 2 Score = 0.999). Also, the recently established 'Combined Annotation Dependent Depletion' (CADD) score, 35 which combines information from in total 63 annotation sources including functional data from ENCODE, calculated the variants effect to be among the most harmful 1% variants in the whole genome (CADD-Phred = 26.7). Importantly, the RBM20 variant carrier did not show a pathogenic variant in any other cardiomyopathy disease gene. 1 To further elucidate the potential effect of the variant, we performed expression analysis of the mutant and wild-type allele. By mRNA sequencing of myocardial tissue of both patients, we show that the wild-type and mutant allele are expressed at comparable levels, suggesting that RNA-decay is not the pathomechanism involved ( Figure  4B bottom) . Western blot analysis supported this finding ( Figure 4B  bottom) . Hence, to establish the detected variant as pathogenic in this family, we performed further molecular and functional investigations.
The RBM20 variant p.R634L leads to severe titin mis-splicing and expression of a giant titin protein
To determine a potential downstream causal effect of the nonsynonymous RBM20 variant p.R634L, we performed mRNA deep sequencing in left-ventricular myocardial tissue of the index patient (explanted heart after heart transplantation) and the endomyocardial biopsy of his mother ( Figure 5A ). The two LVNC cases (blue line) and unaffected controls (red line) did not differ in the splicing patterns of important structural and sarcomeric cardiac genes (see Supplementary Figure S6 ). However, TTN transcripts were significantly altered in their splicing pattern, as shown by the DPSI (green line). By percent-spliced-in (PSI) analysis, the region of mis-splicing could be mapped to the I-band region of titin (PEVK and immunoglobulin-rich region), confirming the hypothesis that the p.R634L variant alters titin splicing predictably by reduced exon skipping.
To further prove the functional relevance of the rare RBM20 variant, we next performed targeted in-vitro transcript-splicing assays ( Figure 5B) . To do so, we cloned wild-type and the three predicted damaging variants (p.R634L, p.P798L, and p.P1105L) constructs and expressed them together with a titin subfragment, which was tagged by sequences coding for Ranilla and Firefly-Luciferase, respectively. As shown in Figure 5C , the p.R634L mutant constructs (Aminoacid numbering based on rat RBM20 sequence: R637L) lead to a strong increase of the ratio Luciferase/Ranilla Luminescence, similar to the positive control (P641L), indicating highly defective splicing activity with reduced exonskipping, which is predicted to result in a longer titin isoform as seen in the RNA-seq experiments and which was consecutively validated by splice-analysis of the mini-gene constructs ( Figure 5D ).
To substantiate this finding, we performed agarose protein gel electrophoresis of isolated protein from the myocardial specimens of the two available LVNC patients. While titin isolated from wild-type tissue contains mainly the shorter N2B form and to a lesser extent the longer N2BA isoforms, both affected patients showed a marked shift towards a very high-molecular-weight titin protein. This socalled giant N2BA isoform is not present in controls or RBM20-mutation negative patients with DCM ( Figure 6 ) and is only expressed due to defective RBM20.
Discussion
Cardiomyopathies are complex diseases that require detailed clinical investigations to delineate the individual subtype and disease aetiology. While there is consensus about the diagnostic criteria for dilated, 36 hypertrophic 37 and arrhythmogenic 38 As shown by PSI analysis, a strong exon inclusion rate is found in the I-band region of titin (DPSI, green line), which is predicted to result in an abnormally long titin protein.
(B) Splicing activity of RBM20 was determined by a dual luciferase splicing assay (DLR). In case of a functional (wild-type) RBM20, Luciferase activity is diminished, whereas defective (LOF, loss of function) RBM20 will lead to a high Luciferase activity. (C) PEVK exon 4-13 splice reporter in HEK293.EBNA cells without RBM20 (CTRL), wild-type RBM20 (WT) and RBM20 mutations (R637L and P641L, corresponding to human R634L and P638L) (n = 8). The high Luciferase activity indicates a detrimental effect of the variants on RBM20. One-way analysis of variance (ANOVA) test P < 0.001 (***), P < 0.01 (**), P < 0.05 (*), P = 1.1102e -16 (D) Splicing activity of rat RBM20 as determined by RT-qPCR on genomic minigene of human TTN exon 241-243 in HEK293 (n = 3).
One-way ANOVA test P < 0.001 (***), P < 0.01 (**), P < 0.05 (*), P = 2.0505e -09
. (E) Exon structure and functional domains of rat RBM20. (F) Sequence conservation in the RS region of RBM20. Dots indicate patient mutations affecting amino acids R637L (red) and P641L (blue). AA, amino acid; CTRL, control; f.c., fold change; FLuc, firefly luciferase; MHC, myosin heavy chain; RLuc, renilla luciferase; RRM, RNA recognition motif; RS, argenin/serin rich region; WT, wildtype; ZnF, zinc finger; PSI, percent spliced-in. sudden cardiac death. 7 Altogether, these facts led to inconsistent recommendations for diagnosis and therapy, for instance regarding prophylactic ICD implantation or oral anticoagulation. In our cohort, we find 10.3% of patients with thromboembolism during the whole observational period. Whether these incidents were caused by thrombus formation in the deep recessi of the left ventricle as observed in one of our cases that underwent heart transplantation or by undetected AF cannot be finally concluded. In 33% of patients with TIA/stroke, we did not detect AF even after repeat Holter monitoring and 4.5% (2 from 44) of patients free of AF (baseline and follow-up) did develop systemic embolism.
The patients were furthermore frequently affected by potentially life threatening ventricular arrhythmias. VT/VF was documented at least once in as many as 35 .3% of cases till the end of the follow-up time, which is in agreement with several previous reports. 39 A comparison between the LVNC cohort and an age-matched DCM cohort showed significantly higher rates of HF associated events in LVNC. This finding is not explained by LVEF alone, which was higher in the LVNC group. It can only be speculated that the different myocardial properties (non-compaction, fibrosis) play a role as substrate for arrhythmias. 39 In cMRI scans of the here enrolled patients, as many as 66.7%, had LGE as indicator of myocardial fibrosis. The data presented on clinical outcomes should encourage physicians, independent of the genotype, to routinely follow-up symptomatic LVNC cases-especially in case of concomitant reduction in LVEF-by repeat Holter-ECG to detect atrial and ventricular arrhythmias. 2 Besides the clinical risk stratification, genetic information may aid the process of diagnosis, predictive testing of relatives and prognostication in LVNC cases. The present study provides for the first-time estimations of the contribution of the known disease genes in a larger cohort using uniform next-generation sequencing. Following stringent criteria defined by the 'American College of Medical Genetics and Genomics' (ACMG), we show that 38.2% of patients have a pathogenic variant in one of six known disease genes. For titin, we identified a role of truncating variants that were previously not known to cause non-compaction cardiomyopathy. Taking this class of genetic variation into account, TTN variants are the most frequent cause for LVNC, showing an odds ratio that is expected for Mendelian disease and suitable for genetic counselling. By transcriptome sequencing of the TTN mutation carriers, we show that the mutant alleles undergo complete or partial nonsense-mediated RNA decay. In case of the two patients with the pathogenic RBM20 variant p.R634L, we demonstrate the consistent change of titin protein expression due to transcriptomic alteration of its messenger RNA, rendering loss-of-function and dominant negative changes in titin a pathomechanisms in LVNC. Although the small numbers do not allow a final conclusion, carriers of pathogenic TTN, LMNA, and RBM20 variants did show unfavourable outcomes, which is in-line with observations made in DCM. LVNC shares many symptoms and clinical findings with other cardiomyopathies. Towbin et al. 39 characterized the phenotypic expressivity of LVNC and identified distinct subtypes including benign LVNC with preserved systolic and diastolic function, dilated LVNC, hypertrophic LVNC, restrictive LVNC, and LVNC with arrhythmia. The reasons for this remarkable variability in clinical findings are not understood, but may be due to the underlying pathogenic variant or the genetic background. In the present study, we could investigate 95 patients mainly with dilated LVNC phenotypes, which is to our knowledge the largest series available. The reason why the pathogenic alleles for RBM20 and TTN did result in a LVNC phenotype and not classical DCM is not finally answered. Titin mutations were not only found to be a frequent cause of DCM 40 but are also related to Peripartum Cardiomyopathy (PPCM), indicating that yet unknown additional factors are involved. Titin is a high-molecular weight protein in striated muscles, which spans half of the sarcomere from the Z-disc to the M-band. Titin is required for proper sarcomere assembly, force transmission and confers to sarcomere elasticity. 41 The TTN gene contains 363 exons and is expressed as different isoforms generated by alternative splicing. It is important to know that titin undergoes significant changes in its isoform expression during embryogenesis and at the time of birth. We are only at the beginning of understanding the machinery that dynamically adapts the exons of titin during these important stages of haemodynamic alterations, but it is known that a very tight regulation of exon-numbers is required. The human heart normally expresses different major titin isoforms, two during embryonic development and three after birth. In the fetal phase, heart tissue expresses the N2BA-N1 isoform (3.7 MDa), which is replaced by the neonatal isoform (N2BA-N2, 3.6 MDa) and later the adult isoforms, N2BA-A1 and -A2 (3.2-3.4 MDa) and N2B (3.0 MDa). 26, 42 The N2BA isoform contains more extensible elements in the I-band and is less rigid compared with the N2B isoform, but also is structurally weaker. 43 We observed in our data that the Clinical genetics and outome of LVNC splicing patterns in distinct regions of titin are significantly different in LVNC patients compared with DCM patients with RBM20 variants. It may be a matter of TTN gene dose and protein function 26 that is present during development or by additional genetic background variation that disturb embryogenesis or adaptive hypertrophic growth during the stress of cardiac failure, ultimately leading to LVNC. 44 RBM20 is a key cardiac splice regulator that controls the processing of several important transcripts. Hence, mutations in RBM20 can result in mis-splicing of several targets, often leading to progressive DCM with conduction diseases as well as atrial or malignant ventricular arrhythmia. 26, 45 Until now, there were to best of our knowledge no described cases of LVNC due to RBM20 mutations. In the current study, we could identify a novel non-synonymous variant in Exon 9 of RBM20 that results in significantly altered splicing-regulator activity.
Other coding variants that were identified in this cohort (RBM20 p.P798L, and p.P1105L) did not show altered titin splicing, at least not in the assays applied here (see Supplementary material online, Figure S7 ). The majority of known RBM20 mutations are localized in exon 9, which functionally disrupts normal RNA splicing of target genes. 26 However, the exact mechanisms leading to DCM as well as LVNC in RBM20 mutation carriers are still not completely understood. Li et al. 46 proposed that RBM20 regulates titin alternative splicing by exon skipping or exon shuffling. RBM20 binds to specific regions of titin pre-mRNA and inhibits introns from being spliced out. Following this step, the 5' and 3' splice-sites of the exons flanking the RBM20-repressed region splice with each other to complete the alternative splicing process. Brauch et al. 45 were the first to report RBM20 mutations in DCM patients, most having high morbidity and mortality. In RBM20 deficient animal models an increase of subendocardial fibrosis has been reported, accompanied by electrical abnormalities such as conduction disease or ventricular arrhythmia. 26 In the family reported here, we found severe endomyocardial fibrosis and progressive LVNC with dilated cardiomyopathy, heart failure and ventricular arrhythmia. We showed that RBM20 p.R634L variant leads to the production of abnormally giant TTN isoform (G-N2BA). It is known that this isoform causes an increase in TTN elasticity that has implications for diastolic function and also the Frank-Starling mechanism. Furthermore, the flaccid titin filament causes a compensatory increase in collagen biosynthesis and leads to fibrosis and arrhythmia as we could observe in these two patients. 26 Besides the findings discussed above, we further detected variants in genes that have previously been reported to result in a LVNC phenotype in animal models (see Supplementary material online, Figure S5 ). The nuclear receptor corepressor 2 (NCOR2) is facilitating the recruitment of histone deacetylases (HDACs) to DNA promoters. In a NCOR2 loss of function mouse model, the compact zone formation of the myocardium was severely affected. 47 We could report here four non-synonymous SNVs human patients, rendering NCOR2 a highly likely new disease gene for LVNC. The same is true for variants found in the Xin actin-binding repeat containing 2 (XIRP2), 48 but further functional investigations and family studies are required to provide the same level of evidence as we have shown in this study for RBM20 and titin. The present study highlights the role of mis-sense and non-sense variants in the titin gene and titin-interacting partner proteins (Obscurin, RBM20). We show that 19% of all LVNC cases are caused by TTN variants (mainly truncating) that only partly underlie NMD. In the family with an aggressive LVNC course, we show by multiple lines of evidence the pathogenic role of RBM20 p.R634L. The pathogenicity involves most obviously severe titin mis-splicing, resulting in a mechanically altered elastic filament protein. Importantly, the splicing patterns observed in LVNC patients, is in distinct regions of TTN different compared with DCM patients with RBM20 variants. Although speculative, these minute changes in TTN isoforms caused by RBM20 or TTN variants may explain why some patients develop DCM while others are presenting with a LVNC phenotype (see Supplementary material online, Figure S8) . It is important to further the understanding how different alleles in the same gene can result in significantly differing cardiac phenotypes, which is the case for several other disease genes such as MYH7, MYBPC3, LMNA, or SCN5A to name only few examples. As such, we investigated all families for overlapping phenotypes with HCM. In one family we for instance detected the known HCM causing variant MYH7 p.R719W. The index case was available for phenotypic analysis and presented an abnormal septal wall thickness of 12 mm. Although not fulfilling the diagnostic criteria of HCM, this may indicate that there is not only a genotypic but also phenotypic overlap.
Potential limitations
There is an on-going and controversial debate whether LVNC is a morphological trait of normal variation, adaptive mechanism to physiological growth stimuli, subtrait of a major cardiomyopathy such as DCM or distinct cardiomyopathy. When applying morphological criteria only, the presence of non-compaction in population-based samples is far higher than expected for a detrimental disease. 3 On the other hand, there are several retrospective studies showing progressive disease and bad prognosis in non-compaction patients. The difficult, but utterly important discrimination of both extremes is not addressed in current guidelines, leaving cardiologists alone in establishing the correct diagnosis. In our patient series, we included patients that were referred to our tertiary centres and were mostly symptomatic at the time of diagnosis or had pathological findings suggestive of a disease (biomarker increase, ECG alterations). Hence, there is a potential referral bias that might explain the bad prognosis of our patients. To control for this effect, we included age-matched DCM patients from our centres. Importantly, the prognosis of DCM patients was favourable in comparison to LVNC although LVEF was better in our LVNC cohort. Whole-exome sequencing could be performed in 27 affected relatives of 68 index patients. Not all relatives could be genotyped in familial cases due to lack of biomaterial or informed consent. Due to the missing co-segregation data in some families, the rate of 'variants with unknown significance' is considerably high. Furthermore, it is currently unclear how particular RBM20, TTN, or other pathogenic variants lead to LVNC and not to other cardiomyopathy phenotypes and how the mutation frequencies would translate to another LVNC cohort with milder phenotypes. It is speculated that alternative titin isoforms arise from truncating mutations that may, besides a loss-offunction mechanism of the main isoform, interfere in a dominant negative mode. Additionally, the genetic background of patients could modify the phenotype expression. Long-read transcriptome sequencing and ribosomal profiling are thought to likely answer these questions in the nearer future, since animal models for noncompaction are sparse and partly provide non-reproducible
